摘要
目的探究依达拉奉联合高压氧治疗进展型脑梗死的临床疗效。方法选取2014年11月至2015年10月昆山市第一人民医院收治的进展型脑梗死患者90例,依据抽签法随机分为观察组和对照组,各45例。所有患者均予抗血小板、营养神经、降压、控制血糖、维持水电解质平衡、脱水等常规治疗,对照组在常规治疗的基础上应用高压氧(每次30 min,每日2次)治疗;观察组在常规治疗的基础上加用依达拉奉(30 mg,每日2次,静脉滴注)联合高压氧治疗(同对照组)。两组患者均治疗14 d,比较两组患者的临床疗效,比较治疗前后美国国立卫生院卒中评分(NIHSS)、日常生活能力评估指标[Barthel指数(BI)]和血流动力学变化,以及不良反应发生情况。结果治疗后,观察组总有效率显著高于对照组[95.6%(43/45)比80.0%(36/45),P<0.05]。治疗后30 d,观察组NIHSS评分显著低于对照组[(7.4±0.8)分比(10.5±1.0)分],BI评分显著高于对照组[(75.3±5.8)分比(64.5±4.2)分],差异有统计学意义(P<0.01)。观察组纤维蛋白原、D-二聚体显著低于对照组[(2.30±0.50)g/L比(3.03±0.62)g/L,(1.26±0.25)mg/L比(1.88±0.32)mg/L],差异有统计学意义(P<0.01)。两组治疗期间均未出现明显不良反应。结论依达拉奉联合高压氧治疗进展型脑梗死临床疗效确切,可促进神经功能恢复,有效改善患者血流动力学,无明显不良反应,值得临床推广。
Objective To investigate the clinical efficacy of edaravone combined with hyperbaric oxygen in the treatment of cerebral infarction. Methods Total of 90 patients with progressive cerebral infarction admitted to Kunshan First People＇s Hospital from Nov. 2014 to Oct. 2015 were included in the study and divided into an observation group and a control group according to the sortition method, 45 cases in each group. All patients were given anti-platelet, nutrition nerve, anti-hypertension, blood sugar control, maintenance of water electrolyte balance, dehydration treatment, and so on. The control group was given hyperbaric oxygen therapy（30 rain/time,2 times/d） on the basis of the routine treatment, while the observation group was treated with edaravone（30 mg,2 times/d, intravenous drip） combined with hyperbaric oxygen therapy （ 30min/time,2 times/d）. Both groups were treated for 14 days, and the clinical efficacy, the National Institutes of Health Stroke Scale（ NIHSS）, Barthel index（BI） and blood theology changes of the two groups were compared before and after treatment, as well as adverse reactions. Results The total effective rate of the observation group was significantly higher than the control group [ 95.6% （43/45） vs 80. 0% （36/45） ,P 〈0. 05 ]. 30 days after treatment, the NIHSS score and BI score in the observation group were significantly better than the control group [（7.4±0.8） score vs （10.5 ±1.0） score,（75.3±5.8） score vs （64.5 ± 4.2） seore,P 〈0. 05]. The fibrinogen and D-dimer of the observation group were significantly better than the control group [ （2.30 ±0. 50） g/L vs （3.03 ±0.62） g/L, （ 1.26 ± 0.25 ） mg/L vs （ 1.88 ± 0.32 ） mg/L,P 〈0.05 ]. There was no obvious adverse reactions in the two groups during the treatment period. Conclusion Edaravone combined with hyperbaric oxygen in treating progressive cerebral infarction has definite clinical curative effect, and no obvious adverse reactions, which can promote the nervous func
出处
《医学综述》
2016年第24期4936-4939,共4页
Medical Recapitulate
关键词
进展型脑梗死
依达拉奉
高压氧
Progressive cerebral infarction
Edaravone
Hyperbaric oxygen
